import 'package:drtest/models/question/question_model.dart';

class DrugDosingModel {
  DrugDosingModel({
    this.drugId = 0,
    this.drugName = "",
    this.drugDose = "",
    required this.param,
  });
  int drugId;
  String drugName;

  String drugDose;
  DrugDosingParams param;
}

enum DrugParamTypeEnum { button, page }

class DrugDosingParams {
  DrugDosingParams({
    this.title = "",
    this.desc = "",
    this.footer = "",
    this.page = "",
    this.buttonTitle = "",
    this.msg = "",
    this.params = const [],
    this.type = DrugParamTypeEnum.button,
  });

  String title;
  String desc;
  String footer;
  String page;
  List<DrugDosingParams> params;
  DrugParamTypeEnum type;
  String buttonTitle;
  String msg;
}

List<DrugDosingModel> drugDosing(TestModel model) {
  var msg1 = """● HIT extremely unlikely.
● Evaluate for other causes of thrombocytopenia.
● Continue to assess HIT probability.
● Can restart/ continue  heparin if clinically indicated (UpToDate).""";

  var extra3 = DrugDosingParams(
      title: "Concurrent HIT & Thrombosis",
      desc: "Is there a thrombosis? (arterial or venous}",
      params: [
        DrugDosingParams(
            buttonTitle: "Yes",
            msg:
                "Give non-heparin anticoagulant for at least 3 months (UpToDate)."),
        DrugDosingParams(
            buttonTitle: "No",
            msg:
                "Give non-heparin anticoagulant for at least 4 weeks (UpToDate).")
      ]);

  var extra2 = DrugDosingParams(
    desc: "Is there a suspect for HIT?",
    params: [
      DrugDosingParams(
        buttonTitle: "Yes",
        title: "4Ts Score Calculator",
        params: [
          DrugDosingParams(
              desc: """4Ts score Calculator
          (UpToDate)
          Calculator: 4Ts score for calculating the pretest probability of heparin-induced thrombocytopenia (HIT)""",
              page: "/ts_dosing",
              params: [
                DrugDosingParams(
                  desc: "What is the ELISA result?",
                  title: "ELISA testing for HIT diagnosis",
                  params: [
                    DrugDosingParams(
                      buttonTitle:
                          "OD≥ 2 OR OD≥ 1.5 with high probability 4Ts score.",
                      msg: "HIT confirmed (UpToDate)",
                      desc: extra3.desc,
                      params: extra3.params,
                      title: extra3.title,
                    ),
                    DrugDosingParams(
                        title: "Functional HIT Assay",
                        buttonTitle:
                            "OD between 0.6 and 1.99 OR Between 0.6 and 1.49 with high probability 4Ts score.",
                        msg:
                            "● Intermediate result.\n● Order functional HIT assay. (e.g. SRA, or HIPA)",
                        desc: "What is the functional assay result?",
                        params: [
                          DrugDosingParams(
                            buttonTitle: "Positive",
                            msg: "HIT confirmed (UpToDate)",
                            desc: extra3.desc,
                            params: extra3.params,
                            title: extra3.title,
                          ),
                          DrugDosingParams(buttonTitle: "Negative", msg: msg1),
                        ]),
                    DrugDosingParams(buttonTitle: "OD < 0.6", msg: msg1),
                  ],
                ),
              ]),
        ],
      ),
      DrugDosingParams(buttonTitle: "No")
    ],
  );

  var extra4 = DrugDosingParams(
      title: "Platelet count monitoring during Enoxaparin treatment",
      desc: "Is the patient case of major surgery or major trauma ?",
      params: [
        DrugDosingParams(
          title: "Suspect for HIT (Enoxaparin)",
          buttonTitle: "No",
          msg: "Suggest against platelet count monitoring (UpToDate).",
          desc: extra2.desc,
          params: extra2.params,
        ),
        DrugDosingParams(
          title: "Suspect for HIT (Enoxaparin)",
          buttonTitle: "Yes",
          msg:
              """Consider Platelet count monitoring every 2 to 3 days from day 0 through day 14.
(Ref: Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances 2018; 2:3360.), UpToDate""",
          desc: extra2.desc,
          params: extra2.params,
        ),
      ]);

  var extra1Msg =
      """Consider Platelet count monitoring every 2 to 3 days from day 0 through day 14.
(Ref: Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances 2018; 2:3360., UpToDate)

Baseline platelet count and a repeat platelet count within 24 to 48 hours is recommended.
""";

  var extra1 = DrugDosingParams(
    desc: "Any of the following scenarios present?",
    params: [
      DrugDosingParams(
        title: "Suspect for HIT (UFH)",
        buttonTitle: "● Medical or obstetric patients.",
        msg: extra1Msg,
        desc: extra2.desc,
        params: extra2.params,
      ),
      DrugDosingParams(
        title: "Suspect for HIT (UFH)",
        buttonTitle: "● Major surgery or major trauma patients.",
        msg: extra1Msg,
        desc: extra2.desc,
        params: extra2.params,
      ),
      DrugDosingParams(
        title: "Suspect for HIT (UFH)",
        buttonTitle: "● History of receiving UFH  in the past 100 days.",
        msg: "Suggest against platelet count monitoring.\n(UpToDate)",
        desc: extra2.desc,
        params: extra2.params,
      ),
    ],
  );

//   var extra1 = DrugDosingParams(
//     desc: """Any of the following scenarios present?
// ● Medical or obstetric patients.
// ● Major surgery or major trauma patients.
// ● History of receiving UFH  in the past 100 days.""",
//     params: [
//       DrugDosingParams(
//         msg:
//             """Consider Platelet count monitoring every 2 to 3 days from day 0 through day 14.
// (Ref: Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances 2018; 2:3360., UpToDate)

// Baseline platelet count and a repeat platelet count within 24 to 48 hours is recommended.
// """,
//         buttonTitle: "Yes",
//         desc: extra2.desc,
//         params: extra2.params,
//       ),
//       DrugDosingParams(
//         msg: "Suggest against platelet count monitoring.\n(UpToDate)",
//         buttonTitle: "No",
//         desc: extra2.desc,
//         params: extra2.params,
//       )
//     ],
//   );

  var extra6 = DrugDosingParams(params: [
    DrugDosingParams(
        buttonTitle: "INR still not in range?",
        msg:
            """● Assessment of medication adherence, intercurrent illness, new or recently adjusted medications, dietary changes, and alcohol intake.
● Education/counselling and more frequent INR checks is critical. (ESC AF 2020 IIa B)
● Cigarette smoking IS associated with less time in therapeutic range for patients on warfarin. (AHA/ACC/ACCP/HRS 2023)
● For patients with AF receiving warfarin, a target INR between 2 and 3 is recommended, as well as optimal management of drug-drug interactions, consistency in vitamin K dietary intake, and routine INR monitoring to improve time in therapeutic range and to minimize risks of preventable thromboembolism or major bleeding. (AHA/ACC/ACCP/HRS 2023, 1 B-R)
● Switching to a NOAC but ensuring good adherence and persistence with therapy is another option. (ESC AF 2020 IIa B)""")
  ]);

  var warfarinMaintenanceDosing = DrugDosingParams(
    desc: "What is the INR level?",
    params: [
      DrugDosingParams(
          buttonTitle: "< 1.5",
          msg:
              "Give extra one- time daily dose and increase weekly dose by 10-20 %.",
          params: extra6.params),
      DrugDosingParams(
          buttonTitle: "1.5-1.9",
          msg:
              "Increase weekly dose by 5- 15 %.\n(may give extra one -time daily dose)",
          params: extra6.params),
      DrugDosingParams(
          buttonTitle: "2.0-3.0",
          msg: "Maintain current dose.",
          params: extra6.params),
      DrugDosingParams(
          buttonTitle: "3.1-4.0",
          msg: "Hold up to one daily dose and decrease weekly dose by 5-20%.",
          params: extra6.params),
      DrugDosingParams(
          buttonTitle: "4.1-5",
          msg: "Hold up to two daily dose and decrease weekly dose by 10-20%.",
          params: extra6.params),
      DrugDosingParams(
          buttonTitle: "≥ 5",
          msg: "Hold until INR is 2-3, and decrease daily dose by 10-20%.",
          params: extra6.params),
    ],
  );

  var extra5 = DrugDosingParams(params: [
    DrugDosingParams(
      title: "Initial target INR not reached?",
      buttonTitle: "What is the maintenance dose?",
      desc: warfarinMaintenanceDosing.desc,
      params: warfarinMaintenanceDosing.params,
    ),
    DrugDosingParams(
        title: "Maintenance target INR not reached?",
        buttonTitle: "INR still not in range?",
        msg:
            """● Assessment of medication adherence, intercurrent illness, new or recently adjusted medications, dietary changes, and alcohol intake.
● Education/counselling and more frequent INR checks is critical. (ESC AF 2020 IIa B)
● Cigarette smoking IS associated with less time in therapeutic range for patients on warfarin. (AHA/ACC/ACCP/HRS 2023)
● For patients with AF receiving warfarin, a target INR between 2 and 3 is recommended, as well as optimal management of drug-drug interactions, consistency in vitamin K dietary intake, and routine INR monitoring to improve time in therapeutic range and to minimize risks of preventable thromboembolism or major bleeding. (AHA/ACC/ACCP/HRS 2023, 1 B-R)
● Switching to a NOAC but ensuring good adherence and persistence with therapy is another option. (ESC AF 2020 IIa B)"""),
  ]);

  List<DrugDosingModel> list = [];

  //UFH
  list.add(
    DrugDosingModel(
        drugId: 2,
        drugName: "UFH Dosing",
        param: DrugDosingParams(params: [
          DrugDosingParams(
            page: "/ufh_dosing",
            title: "UFH Monitoring",
            params: [
              DrugDosingParams(
                page: "/ptt_dosing",
                params: [
                  DrugDosingParams(
                    title: "UFH Resistance",
                    desc:
                        "More than 25 unit/kg/hour required while not reaching aPTT in range ?\nOr\n>35,000 units of heparin per 24 hours, excluding initial bolus doses?",
                    params: [
                      DrugDosingParams(
                        title: "UFH Resistance Count",
                        desc: "Is Anti Xa level between 0.35 - 0.67 IU/ml?",
                        buttonTitle: "Yes",
                        params: [
                          DrugDosingParams(
                            buttonTitle: "Yes",
                            msg: "Continue with current dose.",
                            desc: extra1.desc,
                            params: extra1.params,
                            title:
                                "Is there a need for platelet count monitoring during UFH treatment?",
                          ),
                          DrugDosingParams(
                            buttonTitle: "No",
                            msg: """● Investigate reason for UFH resistance.
● Antithrombin replacement therapy might be considered.
● Consider switching to a non-heparin anticoagulant.
(UpToDate)""",
                            desc: extra1.desc,
                            params: extra1.params,
                            title:
                                "Is there a need for platelet count monitoring during UFH treatment?",
                          ),
                        ],
                      ),
                      DrugDosingParams(
                        buttonTitle: "No",
                        desc: extra1.desc,
                        params: extra1.params,
                        title:
                            "Is there a need for platelet count monitoring during UFH treatment?",
                      ),
                    ],
                  )
                ],
              ),
            ],
          ),
        ])),
  );

  //LMWH
  list.add(
    DrugDosingModel(
        drugId: 3,
        drugName: "Enoxaparin",
        param: DrugDosingParams(title: "Enoxaparin Dosing", params: [
          DrugDosingParams(
            title: "Enoxaparin Dosing",
            page: "/lmwh_dosing",
            params: [
              DrugDosingParams(
                title: "Is there a need for Enoxaparin monitoring?",
                desc: """Any of the following scenarios present?
● Patients with BMI ≥40 kg/m2 who are unstable, experience unexpected thromboembolic or bleeding complications, or require prolonged VTE treatment.
● CrCl<30 ml/min.""",
                params: [
                  DrugDosingParams(
                    title: "Anti Xa monitoring for Enoxaparin",
                    buttonTitle: "Yes",
                    msg:
                        "May consider checking anti-factor Xa activity 4 to 6 hours after dosing, following at least the third or fourth dose.",
                    params: [
                      DrugDosingParams(
                        buttonTitle: "Enoxaparin twice daily dosing?",
                        msg:
                            "The therapeutic ranges is generally 0.5 to 1 anti-factor Xa units/mL.",
                        desc: extra4.desc,
                        params: extra4.params,
                        title: extra4.title,
                      ),
                      DrugDosingParams(
                        buttonTitle: "Enoxaparin Once Daily Dosing?",
                        msg:
                            "The therapeutic ranges is generally 1.0-2.0 anti-factor Xa units/mL.",
                        desc: extra4.desc,
                        params: extra4.params,
                        title: extra4.title,
                      ),
                    ],
                  ),
                  DrugDosingParams(
                    buttonTitle: "No",
                    msg:
                        "Generally, anti-factor Xa monitoring is not recommended.",
                    desc: extra4.desc,
                    params: extra4.params,
                    title: extra4.title,
                  )
                ],
              ),
            ],
          ),
        ])),
  );

  //Warfarin
  list.add(
    DrugDosingModel(
      drugId: 1,
      drugName: "Warfarin",
      param: DrugDosingParams(
        title: "Warfarin Dosing/Bridging",
        desc:
            """Is there high risk of thromboembolism including any of the following scenario?
● Prior cerebrovascular event
● Transient ischemic attack
● History of thromboembolism 
● Mechanical heart valve
● Current intracardiac thrombus
           AND
concurrent low risk of ICH?
(UpToDate), (ESC/VHD 2021)""",
        params: [
          DrugDosingParams(
            title: "Warfarin with Bridging",
            buttonTitle: "Yes",
            desc:
                """● Initiation of warfarin with a heparin bridging regimen may be reasonable in these clinical settings.
● Consider warfarin in combination with bridging therapy using UFH or LMWH until therapeutic INR is achieved.
● Bridging therapy should continue for at least 5 days and until therapeutic INR achieved.
● Similar safety and efficacy outcomes have been reported following bridging with either UFH or LMWH.
● Once a stable therapeutic INR is reached for >_24 h, bridging can be discontinued. (ESC VHD 2021)""",
            params: [
              DrugDosingParams(page: "/wafarin_extra"),
            ],
          ),
          DrugDosingParams(
            title: "Warfarin without Bridging",
            buttonTitle: "No",
            desc:
                "It is reasonable to initiate warfarin without heparin bridging.\n(UpToDate)",
            params: [
              DrugDosingParams(
                  title: "Warfarin sensitive & insensitive population",
                  buttonTitle: "Warfarin initial dosing",
                  desc:
                      """Is the patient categorized as sensitive or any of the following present?
● Age ≥ 70
● Malnourish
● Liver or Kidney disease
● Heart failure
● Concurrent medication known to increase warfarin sensitivity (e.g. amiodarone)""",
                  params: [
                    DrugDosingParams(
                      title: "Warfarin initial dose Monitoring (insensitive)",
                      msg:
                          "Start 5 mg daily for the first 2 days and check INR on the 3th day.",
                      desc: "What is the INR on the 3th day?",
                      buttonTitle: "No",
                      params: [
                        DrugDosingParams(
                          buttonTitle: "< 1.5",
                          msg:
                              "Increase dose to 7.5-10 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "1.5-1.9",
                          msg:
                              "Continue with 5 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "2.0-3.0",
                          msg:
                              "Decrease dose to 2.5 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "3.1-4.0",
                          msg:
                              "Decrease dose to 1.25 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "> 4.0",
                          msg: "Hold. Check INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                      ],
                    ),
                    DrugDosingParams(
                      title: "Warfarin initial dose Monitoring (sensitive)",
                      msg:
                          "Start 2.5 mg daily for the first 2 days and check the INR on the 3th day.",
                      desc: "What is the INR on the 3th day?",
                      buttonTitle: "Yes",
                      params: [
                        DrugDosingParams(
                          buttonTitle: "< 1.5",
                          msg:
                              "Increase dose to 5- 7.5 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "1.5-1.9",
                          msg:
                              "Continue with 2.5 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "2.0-3.0",
                          msg:
                              "Decrease dose to 1.25 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "3.1-4.0",
                          msg:
                              "Decrease dose to 0.5 mg daily.\nCheck INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                        DrugDosingParams(
                          buttonTitle: "> 4.0",
                          msg: "Hold. Check INR in the next 2-3 days.",
                          params: extra5.params,
                          title: extra5.title,
                        ),
                      ],
                    ),
                  ]),
              DrugDosingParams(
                  title:
                      "Warfarin maintenance dose monitoring (Target INR=2-3)",
                  buttonTitle: "Warfarin maintenance dose",
                  desc: warfarinMaintenanceDosing.desc,
                  params: warfarinMaintenanceDosing.params),
            ],
          ),
        ],
      ),
    ),
  );

  //Edoxaban
  list.add(
    DrugDosingModel(
      drugId: 5,
      drugName: "Edoxaban",
      param: DrugDosingParams(title: "Edoxaban Dosing", params: [
        DrugDosingParams(title: "Edoxaban Dosing", page: "/edoxaban_dosing"),
      ]),
    ),
  );

  //Dabigatran
  list.add(
    DrugDosingModel(
      drugId: 6,
      drugName: "Dabigatran",
      param: DrugDosingParams(title: "Dabigatran Dosing", params: [
        DrugDosingParams(
            title: "Dabigatran Dosing", page: "/dabigatran_dosing"),
      ]),
    ),
  );

  //Apixaban
  list.add(
    DrugDosingModel(
      drugId: 4,
      drugName: "Apixaban",
      param: DrugDosingParams(title: "Apixaban Dosing", params: [
        DrugDosingParams(title: "Apixaban Dosing", page: "/apixaban_dosing"),
      ]),
    ),
  );

  //Rivaroxaban
  list.add(
    DrugDosingModel(
      drugId: 7,
      drugName: "Rivaroxaban",
      param: DrugDosingParams(title: "Rivaroxaban Dosing", params: [
        DrugDosingParams(
            title: "Rivaroxaban Dosing", page: "/rivaroxaban_dosing"),
      ]),
    ),
  );

  //4-Factor PCC dosing
  list.add(
    DrugDosingModel(
      drugId: 8,
      drugName: "4-Factor PCC dosing",
      param: DrugDosingParams(params: [
        DrugDosingParams(
            buttonTitle: "Warfarin overdose?",
            params: [DrugDosingParams(page: "/Warfarin4f_dosing")]),
        DrugDosingParams(
            buttonTitle: "Apixaban, Rivaroxaban, Edoxaban overdose?",
            msg:
                "2000 units once or 25 to 50 units/kg (${model.perWeight(25)} to ${model.perWeight(50)})\n(AHA/ACC/ACCP/HRS 2023)"),
      ]),
    ),
  );

  //Activated PCC
  list.add(
    DrugDosingModel(
      drugId: 9,
      drugName: "Activated PCC",
      param: DrugDosingParams(
          desc: """Dabigatran-associated life-threatening bleeding: 
50 units/kg once (${model.perWeight(50)}) (AHA/ACC/ACCP/HRS 2023)"""),
    ),
  );

  //Idarucizumab Dosing
  list.add(
    DrugDosingModel(
      drugId: 10,
      drugName: "Idarucizumab Dosing",
      param: DrugDosingParams(
          desc:
              """● A total of 5 g idarucizumab is administered intravenously in two ready-to-use doses of 2.5 g i.v., administered as two consecutive infusions over 5 to 10 minutes each or as a bolus injection.
● Additional 5 g may be given if reappearance of bleeding with elevated coagulation parameters have been observed or patients require second emergency surgery/procedure and elevated coagulation parameters. (AHA/ACC/ACCP/HRS 2023), (EHRA/NOAC AF 2021)""",
          params: [
            DrugDosingParams(
                buttonTitle:
                    "Which monitoring should be considered after idarucizumab administration?",
                msg:
                    """After 24 hours, dabigatran can be re-started if clinically indicated and feasible, with normal kinetics. 
● Other anticoagulants, including heparins, are not affected by idarucizumab. (EHRA/NOAC AF 2021)"""),
            DrugDosingParams(
                buttonTitle: "When to reinitiate dabigatran?",
                msg:
                    """Consider monitoring including coagulation parameters (aPTT, diluted thrombin time, or ecarin clotting time) between 12 and 24 h to assess redistribution of dabigatran from peripheral to Plasma (EHRA/NOAC AF 2021)"""),
          ]),
    ),
  );

  //Andexanet alfa
  list.add(
    DrugDosingModel(
      drugId: 11,
      drugName: "Andexanet alfa",
      param: DrugDosingParams(
          desc: """
Which of the following clinical scenario exist regarding the last dose of DOAC?

1- Apixaban ≤ 5 mg OR Rivaroxaban ≤ 10 mg OR Edoxaban ≤ 30 mg regardless of the timing of the last dose:
● Consider Low-dose regimen: 400-mg bolus at a target rate of 30 mg/min followed by 4 mg/min for up to 120 min. (AHA/ACC/ACCP HRS 2023), (EHRA/NOAC AF 2021)

2- Apixaban > 5 mg  OR Rivaroxaban > 10 mg OR  Edoxaban > 30 mg and  last dose taken < 8 hours:
● Consider High-dose regimen: 800-mg bolus at a target rate of 30 mg/min followed by 8 mg/min for up to 120 min. (AHA/ACC/ACCP HRS 2023), (EHRA/NOAC AF 2021)

3- Apixaban > 5 mg  OR Rivaroxaban > 10 mg OR  Edoxaban > 30 mg and  last dose taken ≥ 8 hours:
● Consider Low-dose regimen: 400-mg bolus at a target rate of 30 mg/min followed by 4 mg/min for up to 120 min. (AHA/ACC/ACCP HRS 2023), (EHRA/NOAC AF 2021)""",
          params: [
            DrugDosingParams(
                buttonTitle:
                    "Which monitoring should be considered after idarucizumab administration?",
                msg:
                    """Current commercial anti-Xa activity assays are unsuitable for measuring factor Xa activities after andexanet alfa use. (EHRA/NOAC AF 2021)"""),
            DrugDosingParams(
                buttonTitle: "When to reinitiate anti-Xa drugs?",
                msg:
                    """Since anticoagulant activity may re-appear after cessation of the infusion it is currently less clear at what point in time and with which anticoagulant effect FXa  inhibitors or heparin can be (re-)administered following andexanet alpha administration. (EHRA/NOAC AF 2021)"""),
          ]),
    ),
  );

  //Vitamin K dosing
  list.add(
    DrugDosingModel(
      drugId: 12,
      drugName: "Vitamin K dosing",
      param: DrugDosingParams(
          desc:
              """•	FFP may be given if no PCC is available (initial dose 15 to 30 mL/kg), or if the patient is receiving massive transfusions for severe ongoing bleeding. Doses of FFP required to replace coagulation factors often involve multiple units of FFP, which must be thawed and may take hours to administer, with risks of volume overload and transfusion reactions. (UpToDate)
•	Nonbleeding patients should not be given prothrombin complex concentrate (PCC) or Fresh Frozen Plasma (FFP) solely to correct a supratherapeutic INR. (UpToDate)
"""),
    ),
  );
  return list;
}
